CDT (CDT Equity) Research & Development: $5.05 Mil (TTM As of Dec. 2025)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.62
! 5 Warning Signs
View Full Analysis

What is CDT Equity Research & Development?

CDT Equity CDT -12.56% 10 Research & Development is $5.05 Mil as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CDT Equity's Research & Development for the three months ended in Dec. 2025 was $0.75 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $5.05 Mil.

CDT Equity  (NAS:CDT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CDT Equity Research & Development Related Terms

CDT Equity Research & Development Historical Data

* Premium members only.

The historical data trend for CDT Equity's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Research & Development Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.28 0.11 0.09 3.38 5.05

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.92 1.86 1.53 0.75
CDT
10GF Score
CDT Equity Inc CDT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $5.05 Mil mean?
CDT Equity (CDT) has a Research & Development of $5.05 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CDT Equity and its competitors.
Is CDT Equity's Research & Development too high?
CDT Equity's current Research & Development is $5.05 Mil. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Research & Development compare to PULM and ADIL?
CDT Equity's Research & Development of $5.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CDT Equity and its competitors. CDT Equity's current Research & Development is $5.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Research & Development of $5.05 Mil. The current Research & Development is $5.05 Mil. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CDT Equity (CDT), the current Research & Development is $5.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62
Price